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Background: Low and intermediate grade chondrosarcomas are relative rare bone tumours. About 5-12% of all
chondrosarcomas are localized in base of skull region. Low grade chondrosarcoma has a low incidence of distant
metastasis but is potentially lethal disease. Therefore, local therapy is of crucial importance in the treatment of skull
base chondrosarcomas. Surgical resection is the primary treatment standard. Unfortunately the late diagnosis and
diagnosis at the extensive stage are common due to the slow and asymptomatic growth of the lesions.
Consequently, complete resection is hindered due to close proximity to critical and hence dose limiting organs
such as optic nerves, chiasm and brainstem. Adjuvant or additional radiation therapy is very important for the
improvement of local control rates in the primary treatment. Proton therapy is the gold standard in the treatment
of skull base chondrosarcomas. However, high-LET (linear energy transfer) beams such as carbon ions theoretically
offer advantages by enhanced biologic effectiveness in slow-growing tumours.
Methods/Design: The study is a prospective randomised active-controlled clinical phase III trial. The trial will be
carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.
Patients with skull base chondrosarcomas will be randomised to either proton or carbon ion radiation therapy. As a
standard, patients will undergo non-invasive, rigid immobilization and target volume definition will be carried out
based on CT and MRI data. The biologically isoeffective target dose to the PTV (planning target volume) in carbon
ion treatment will be 60 Gy E ± 5% and 70 Gy E ± 5% (standard dose) in proton therapy respectively. The 5 year
local-progression free survival (LPFS) rate will be analysed as primary end point. Overall survival, progression free
and metastasis free survival, patterns of recurrence, local control rate and morbidity are the secondary end points.
Discussion: Up to now it was impossible to compare two different particle therapies, i.e. protons and carbon ions,
directly at the same facility in connection with the treatment of low grade skull base chondrosarcomas.
This trial is a phase III study to demonstrate that carbon ion radiotherapy (experimental treatment) is not relevantly
inferior and at least as good as proton radiotherapy (standard treatment) with respect to 5 year LPFS in the treat-
ment of chondrosarcomas. Additionally, we expect less toxicity in the carbon ion treatment arm.
Trial Registration: ClinicalTrials.gov identifier: NCT01182753
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Low and intermediate grade chondrosarcomas (9-13% of
all malignant bone tumours) are relative rare bone
tumours. In 5-12% of all cases the chondrosarcomas are
localized in head-and-neck region [1]. The typical sites of
skull base lesions are temporo-occipital junction, parasel-
lar area, spheno-ethmoid region and clivus [2,3]. Due to
hystopathological type chondrosarcomas are divided into
Grade 1 to 3 tumours according to mitotic rates (WHO
classification) with 3 histological subgroups: classic,
mesenchymal and myxoid [2]. The mesenchymal type
has more aggressive growth behaviour and is associated
with a poorer prognosis. Histological differentiation from
chordomas is often difficult and must contain immunhis-
tochemical staining [2,4]. Chordoma is immunopositive
for epithelial markers like cytokeratin and endothelial
membrane antigen (EMA), whereas chondrosarcoma is
negative for both. Both chordomas and chondrosarcomas
can be positive for S-100 and vimentin [5].
Most patients diagnosed are over the age of 40 years.
Low grade chondrosarcoma has a low incidence of dis-
tant metastasis but is potentially lethal disease. Thus,
local therapy has a crucial importance in the treatment of
skull base chondrosarcomas. Surgical resection is the pri-
mary treatment standard. Unfortunately the late diagno-
sis and diagnosis at the extensive size of the tumours are
common due to the slow growth kinetics; most patients
are asymptomatic, or develop symptoms at a late stage of
the disease. Consequently, complete resection is hindered
due to close proximity to critical and hence dose limiting
organs for radiation therapy i.e. optic nerves, chiasm and
brainstem. Adjuvant or additional radiation therapy is
very important for the improvement of local control rates
in the primary treatment even after complete resection
(no compartment resection possible). Anyhow, chondro-
sarcoma have a better outcome and prognosis compared
to chordoma [6,7].
Chondrosarcomas are commonly radioresistant [8],
and high local doses are required for long-term local
control. Image guidance in conformal precision radia-
tion therapy provides a safe technique in the treatment
of base of skull tumours [9]. The highest dose conform-
ality is possible using particle therapy with heavy ions
and protons due to inverted dose profile allowing steep
dose gradients and therefore providing further benefit in
reducing toxicity and irradiation safety.
It is brightly accepted, that proton therapy can be
considered the gold standard for treatment of rare skull-
base tumours like chordoma and low grade chondrosar-
coma [10]. Loma Linda University Medical Center
(LLUMC) [8] the Massachusetts General Hospital
( M G H )i nB o s t o n[ 1 1 ]h a v et h el o n g e s te x p e r i e n c ei n
proton therapy for these entities. 3-year local control for
chondrosarcomas after fractionated proton radiation
therapy in 25 patients at LLUMC was 94% and the
actuarial 5 year survival rate was 100% respectively [11].
The outcome in 229 chondrosarcomas treated with a
combination of proton and photon therapy at MGH/
HCL shows 5-and 10-year local progression free survival
rate of 98% and 94% for chondrosarcomas respectively.
The results are significantly better than in chordomas
treated at the same institution [8].
Proton therapy results from PSI in Villingen, Switzer-
land were published by Weber et al. and Ares et. al. The
data showed 3- and 5-year local control rates of 100% and
94%, respectively. 64 patients, among them 22 patients
with chondrosarcoma were treated to a median target
dose of 68.4 GyE. The 3-year actuarial overall survival rate
for the chondrosarcoma patients was 91% [12,13].
Carbon ions though, have a higher biological effective-
ness than either protons or photons, which is important
in case of radioresistant tumours [14].
Carbon ion therapy is available at the National Insti-
tute of Radiological Sciences (NIRS) in Japan and at
Heidelberger Ionenstrahl-Therapie (HIT) centre. The
report of our Japanese colleagues experience is limited
to 40 patients with chordoma and chondrosarcoma of
the skull base. The patients could be treated effectively
and without serious side effects [15]. NIRS beam deliv-
ery technique relies on passive scanning necessitating
various modulators to adjust for treatment depth and
tissue inhomogeneities within the beam path.
Our experience is based on the clinical work at the
Gesellschaft für Schwerionenforschung (GSI) Darmstadt
in Germany up to July 2008. In comparison to the Japa-
nese centres, the facility at GSI as well as the HIT relies
on active beam delivery using the raster-scan technique.
About 300 patients with base of skull chordomas and
chondrosarcomas have been treated so far. Initially,
these patients were treated within a clinical Phase I/II
study. After the study was able to demonstrate success-
ful treatment, carbon ion therapy became approved as
the best therapy available in Germany. The actuarial
local control rates for the chondrosarcoma patients after
3 and 5 years was 96.2% and 89.8% respectively, the 5
year overall survival rates was 98.2% [16].
Methods/Design
The study plan has been submitted to the ethics com-
mittee of the Medical faculty Heidelberg and is already
approved. Also the positive vote of Bundesamt für
Strahlenschutz (the governmental authority for radiation
protection in Germany) has been already obtained.
T h es t u d yi sad o u b l ea r mp r o s p e c t i v er a n d o m i s e d
clinical phase III study of patients with low/intermediate
grade chondrosarcomas of the skull base. Study patients
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study protocol. After careful review of the patient
reports and results of the additional examinations elig-
ibility of a patient will be determined.
The randomisation will be done using the on-line ran-
domisation tool (Randomizer.at) which is self-serve and
runs exclusively on the Internet. The randomisation will
be performed regarding treatment arms A and B.
Patients will be randomized to the treatment groups
with an equal allocation ratio of 1:1.
As this is an open-label study there will be no blinding
of treatment assignment.
Primary objectives of the study
The primary objective of this study is to evaluate, if the
innovative therapy (carbon ion irradiation) in chondro-
sarcomas is not relevantly inferior to the standard proton
treatment with respect to the 5 year LPFS rate defined as
time from the randomisation to observed local recur-
rence. Withdrawals, lost to follow-ups and patients for
whom no event has occurred at study termination are
treated as censored observations. The censoring date is
given by the last known date at which no event has
occurred for the respective patient. Local recurrence
defined as MRT or CT - morphological tumour progress
in the former irradiated region. It is assumed that the
LPFS rate for the proton therapy is 90%.
Secondary objectives of the study
Assessment of overall survival, progression free and
metastasis free survival, patterns of recurrence, local
control rate and morbidity (acute and late toxicity
(Common Terminology Criteria for Adverse Events:
CTCAE V4.0, RTOG/EORTC for late effects)) are the
second objectives of the study. Plan quality (target cov-
erage, sparing of organs at risk, integral dose) is also a
matter of interest.
Inclusion criteria
- Karnofsky Performance Score ≥60%
- Age >18 years and <80 years
- Informed consent signed by the patient
- Histological confirmation of low/intermediate grade
chondrosarcoma with infiltration of the skull base.
Exclusion criteria
- Inability to understand the aims of the study, no
informed consent
- Prior RT of skull base region
- Other malignancies with disease-free interval < 5
years (excepting pre-cancerous lesions)
- Participation in another trial
- Pregnancy
- Simultaneous CHT or Immunotherapy.
Study concept
Pre-treatment examination such as history and physical
examination including neurological status, histological
confirmation of chondrosarcoma, reference-histopathol-
ogy if necessary, ophthalmologic examination by optic
nerve, chiasm infiltration or by contiguity, audiometry
by auditory channel infiltration or by contiguity, endo-
crinological examination by contiguity to sella turcica
region and MR - Imaging (before) and after operation
will be done or/and collected.
Patients with histologically confirmed low and inter-
mediate grade chondrosarcoma and infiltration of the
skull base which are willing to participate will be
included into our study after verification of the eligibility
centrally at the HIT trial center. These patients are sub-
sequently randomized to one of the two treatment arms
(arm A: carbon ion therapy, arm B: proton therapy).
Carbon ion therapy (Arm A) will be aplicated with a
total target dose of 60 Gy E ± 5% to the PTV1. The
PTV2 will receive a total carbon ion dose of 45 Gy E.
The patients entered in Arm B will receive proton ther-
apy with the same target definition concept. The total pro-
t o nd o s ew i l lb e7 0G yE±5 % .T h eP T V 2w i l lr e c e i v ea
total dose of 50 to 56 Gy E in conventional fractionation.
Accrual period for the trial will be approximately 7
years. Our study design contains one interim analysis
after observation period of approximately 5.5 years. The
study will be terminated early in case of interim analysis
showing 5% smaller rate of the 5 year LPFS of the experi-
mental treatment (carbon ion therapy) in respect to the
5 year LPFS rate of standard treatment (proton therapy).
If it is not a case the study ends with the enrollement of
planned 154 patients. Definite assessments of 5 year
LPFS, primary and secondary endpoints will be per-
formed 12 years after completion of radiation therapy.
Reference Committee
In order to monitor specific aspects of the current trial
t h ef o l l o w i n gR e f e r e n c eD a t aM o n i t o r i n gC o m m i t t e e
(DMC) will be established. The DMC will be composed
of independent experts in the field of radiation oncol-
ogy, assessing the progress of the trial and available
safety data. The mission of the DMC will be to ensure
the ethical conduct of the trial and to protect the safety
interests of patients.
The DMC will meet on a regular basis, i.e. once a
year. Based on its review of available safety data (CRFs)
the DMC will provide the sponsor with written recom-
mendations regarding trial modification, continuation or
termination.
Treatment planning and radiation therapy
Patients will be immobilized using a precision head
mask to ensure high repositioning accuracy of the target
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ton RT. The treatment planning CT (obligate native CT,
CT with contrast facultative) and MR-Examination
(MRT - compulsory sequences - axial T1 post gadoli-
nium and T2 fat saturated or Flair fat saturated) will be
performed in treatment position using the immobilisa-
tion device and will be co-registered. The treatment
planning CT will consist of continuous 3 mm slices
obtained in a stereotactic or virtual simulation set-up.
The delineation of organs at risk and target volume
definition will be done on the basis of CTs and MRI
scans. The CTV1 should include the GTV (entire resi-
dual tumour) and a 1-2 mm safety margin. CTV2
includes the CTV1 with individual safety margin based
on surgical and histological reports, and MR-images to
account for subclinical disease. The PTV will created
adding safety margins around the CTV individually for
each patient. The following organs at risk will be
defined: eyes, optic nerves, chiasm, brainstem, spinal
cord obligatory, temporal lobes, mandible, salivary
glands and others facultative. An overlap of the CTV
and the OAR needs to be avoided.
Carbon ion/Proton RT
Carbon ion RT planning is performed using the treat-
ment planning software including biological plan opti-
mization for carbon ions. Two to maximum four
irradiation fields will be chosen. At HIT the intensity-
controlled raster-scan system will be used for beam
application. Considering the tolerance dose to organs at
r i s kad o s eo f6 0G yE±5 %i n1 9 - 2 1f r a c t i o n sf o rc a r -
bon ions and 70 Gy E ± 5% in 34-36 fractions for pro-
tons will be prescribed to the maximum of the
calculated dose distribution for the target volume
(CTV1). The dose prescription used is related to the iso-
effective dose Gy E using daily fractions of 3 Gy E and a
weekly fractionation of 4-6 × 3 Gy E for carbon ions.
For proton therapy daily fractions of 2 Gy E and a
weekly fractionation of 4-6 × 2 Gy E will be used. Treat-
ment planning aims at coverage of the CTV1 and CTV2
with the 95%-isodose line of the prescribed dose.
Evaluation of DVH for the dose distribution will be
performed with regards to assess plan quality.
Positioning accuracy will be controlled for each frac-
tion using orthogonal x-rays or cone-beam-CTs. Set-up
deviations > 2 mm will be corrected prior to irradiation
by correction with the vector of the robotic table.
Dose constraints to organs at risk for both arms
Dose constraints to organs at risk are estimated consid-
ering the experience of our institution as well as the
data reported by Emami et al. [17]. The dose to the
eyes, temporal lobes, salivary glands, mandible has to be
as low as possible. Optic nerves, chiasm and brainstem
constraint is ≤ 54 Gy. The brainstem surface (1% of
volume) contacting the tumour is allowed to receive >54
Gy, with Dmax ≤ 60 Gy. The doses at the brainstem
center has to be <50 Gy. The spinal cord dose con-
straint is ≤ 45 Gy with 1% of volume allowed to receive
>45 Gy (Dmax ≤ 50 Gy).
Organization and follow-up
Patient data will be collected and documented pseudo-
nymously using electronic data processing (e.g. patient
initials, date of birth and study number) at the study
office at HIT.
The study data as for example all medical reports, RT
documentation and CRF’s will be collected at the study
office at HIT.
Local recurrences will be confirmed radiologically and
histologically whenever possible. At least two medical
doctors (radiation oncologist and/or radiologist) will be
required to judge of the recurrence or toxicity. Each
adverse event occurring in connection with the therapy
has to be documented, independent of the cause.
The first and the second follow-up examination will
be performed 4-6 weeks and 3 months after completion
of RT (follow-up 1 and 2). Follow-up examinations will
then be scheduled after 6 months (follow-up 3), 9-12
months (follow-up 4), and then once a year for further
3 years (follow-up 5, 6 and 7). Additional visits will be
scheduled as necessary. Acute toxicity is assessed at
least weekly during RT and documented at the end of
the RT series, 6 weeks after completion of RT and
3 months after RT. Late toxicity will be documented in
regular intervals of 6 or 12 months during the observa-
tion period. All the patients will be observed for radia-
tion specific acute and late AEs for the time of at least
5 years after irradiation. The maximum grade of toxicity
will be determined for each patient.
The Common Terminology Criteria for Adverse
Events V4.0 (CTCAE V4.0) will be used to grade acute
toxicity from radiation therapy. The criteria are relevant
from the 8th irradiation day until day 90, i.e. until the
1st follow-up visit. Thereafter, the RTOG/EORTC Cri-
teria of Late Effects will be utilized. All acute radiation
effects will be documented on an Acute Radiation
Effect-Form. In addition, the AE-Form and/or SAE-
Form will be filled out.
RTOG/EORTC Late Morbidity Scoring Scheme will
be used to grade toxicity from radiation therapy occur-
ring later than 90 days after its start, i.e. beyond the 1st
follow-up visit. All late radiation effects will be docu-
mented on a Late Radiation Effect-Form. Every patient
will be followed for LPFS and AEs for a time period of
5 years. Furthermore, patients will be followed for survi-
val and locoregional recurrences for a time period of
5 years after completion of the irradiation.
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7 years starting in autumn 2010.
The individual reasons for the study interruption are
patient death or the withdrawal of the patient to partici-
pate in the study. Withdrawals, lost to follow-ups and
patients for whom no event has occurred at study termi-
nation are treated as censored observations. The censor-
ing date is given by the last known date at which no
event has occurred for the respective patient.
With proven recurrence of disease or the development
of distant metastases, the patient will be censored for
our study and will be eligible for any additional appro-
priate therapy or inclusion in other investigative proto-
cols, but should still be followed in order to document
survival and radiation specific AEs.
High incidence of unknown AEs or increase in known
AEs with the disadvantageous proportion between risk
and benefits of the proposed radiation therapy or unaccep-
table high rates of SAEs can terminate the study earlier.
Statistical considerations
This trial is a phase III study to demonstrate that ion
radiotherapy (experimental treatment) is not relevantly
inferior to proton radiotherapy (standard treatment)
with respect to the 5 year LPFS rate. The null-hypoth-
esis to be assessed in confirmatory analysis states that
the 5 year LPFS rate in the experimental treatment
g r o u pi sa tl e a s t5 %l o w e rt h a nt h e5y e a rL P F Sr a t ei n
the standard treatment group. Confirmatory analysis for
the primary end point is based on the intention-to-treat
population. A group-sequential design is applied with
one interim analysis after half of the expected number
of events has occurred to allow for an early stopping of
the study in case of an overwhelming treatment effect.
The stopping rule is according to O’Brien and Fleming
[18]. The one-sided critical level in the interim analysis
is given by 0.26%, and in the final analysis it is given by
2.4%. Test decision is made by comparing the corre-
sponding repeated confidence intervals to the boundary
of the non-inferiority range of -5% (LPFS rate experi-
mental treatment - LPFS rate standard treatment). With
this design, the one-sided overall type I error rate is
controlled by 2.5%. The confidence intervals for the dif-
ferences between the LPFS rates are calculated based on
the log(-log)-transformed Kaplan-Meier estimates of the
rates using Greenwood’s formula to estimate the under-
lying variance [19].
The total sample size of 154 patients provides a
power of 80% to show non-inferiority of the experi-
mental treatment to the standard treatment if the
experimental treatment is in fact superior with respect
to the 5 year LPFS rate by 7% and if the LPFS rate of
the standard treatment group is 90%. Calculation of
the sample size is based on the non-inferiority test for
the differences between rates as described by Farring-
ton and Manning [20].
I ft h ec o n f i r m a t o r ya i mo ft h es t u d yc a n n o tb e
reached, the trial still allows a descriptive head-to-head
comparison of the two treatments, and the inspection of
the confidence interval for the treatment effect enables
to exclude a certain amount of difference in efficacy
between the treatments.
To assess the impact of major protocol deviations, an
analogous analysis of the primary outcome variable will
be performed for the per protocol set. Analysis of the
secondary endpoints as overall survival, progression-free
and metastasis-free survival will be performed analo-
gously to the primary endpoint. The survival curves will
be estimated using the Kaplan-Meier product-limit
method [21].
All documented variables will be analyzed descrip-
tively by tabulation of the measures of the empirical dis-
tributions according to the scale level of the variables.
Descriptive p-values of the corresponding statistical tests
comparing the treatment groups and associated 95%
confidence intervals will be given. The homogeneity of
the treatment groups will be described by comparison of
the demographic data and the baseline values of the
measured variables.
Safety analysis and analysis of toxicity will be based on
the data set of all randomized patients who were treated
with the experimental or the standard treatment at least
once. The safety analysis includes calculation and com-
parison of frequencies and rates of adverse and serious
adverse events reported in the two treatment groups.
All analyses will be done using SAS version 9.1 or
higher.
Discussion
Proton therapy is the standard treatment option in skull
base chondrosarcoma patients after the tumour resec-
tion. Our experience with carbon ion therapy in patients
with chondrosarcomas showed excellent results. How-
ever, until now, it has been not possible to compare
both particles, i.e. protons and carbon ions, directly
within the same facility for the treatment of low grade
skull base chondrosarcomas.
This trial is a phase III study to demonstrate that car-
bon ion radiotherapy (experimental treatment) is not
relevantly inferior and at least as good as proton radio-
therapy (standard treatment) with respect to 5 year LPFS
in the treatment of chondrosarcomas. Additionally, we
expect less toxicity in the carbon ion treatment arm due
to the reduced lateral scattering of the carbon beam.
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